---
schema_version: "secwatch.filing_event.v1"
accession: "0001740797-25-000047"
form_type: "8-K"
ticker: "AVAI"
cik: "0001740797"
company_name: "AVAI BIO, INC."
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:16:16.166309+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Avant Technologies enters joint venture with Austrianova to form Klothonova for Klotho-based therapies

## Summary
- AVAI and Austrianova form Klothonova Inc., a 50/50 joint venture to develop treatments for Alzheimer's, heart disease, cancer, kidney disease, and longevity.
- AVAI will fund Klothonova's operations for 18 months up to $1.5M in exchange for 1.5M shares (50% ownership).
- Austrianova contributes its proprietary cell encapsulation technology and IP as an exclusive license to Klothonova.
- Potential additional $8.5M loan from AVAI for clinical development; if AVAI declines, Austrianova can pursue development outside Klothonova.
- Kenn Kerr named CEO; Walter H. Günzburg, Ph.D., appointed Chairman of the Board.

## SEC filing metadata
- accession: 0001740797-25-000047
- form_type: 8-K
- ticker: AVAI
- cik: 0001740797
- company_name: AVAI BIO, INC.
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740797/000174079725000047/0001740797-25-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740797/000174079725000047/form8_avai.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001740797-25-000047
- JSON: https://secwatch.observer/filing/0001740797-25-000047.json
- Plain text: https://secwatch.observer/filing/0001740797-25-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.